Is marijuana a gateway drug or a misunderstood medicine? This debate just got a whole lot hotter. Republican Representative Mike Lawler (N.Y.) has thrown a wrench into the ongoing discussion about marijuana reclassification, boldly stating that it would be ‘wrong’ for former President Trump to reclassify the drug. But here's where it gets controversial: Lawler’s stance isn’t just about politics—it’s about public health, addiction, and the potential risks of normalizing a substance he believes is a stepping stone to harder drugs.
In a recent interview on NewsNation’s ‘The Hill,’ Lawler told host Blake Burman, ‘I think rescheduling marijuana is a mistake. The reality is, marijuana often serves as a gateway drug. Many individuals who end up using more dangerous substances start their journey with marijuana.’ This claim, while not universally accepted, underscores a deeply divisive issue: should marijuana remain a Schedule I drug, grouped with heroin and LSD, or does it deserve a less severe classification like Schedule III?
And this is the part most people miss: The Biden administration had already initiated efforts to reclassify marijuana as a Schedule III drug, which the Drug Enforcement Administration (DEA) defines as having a moderate to low potential for dependence. Drugs in this category include ketamine and anabolic steroids. However, the process was left unfinished when President Biden left office. Now, Trump is ‘considering’ picking up where Biden left off, reigniting the debate.
Lawler’s argument is further supported by data showing a significant increase in THC concentration—the main psychoactive component in marijuana—over the past few decades. According to the Washington State Liquor and Cannabis Board, average THC levels have jumped from around 5% in the 1990s to 15-20% today. This raises concerns about the potency of modern marijuana and its potential long-term effects.
But here’s the counterpoint: While Lawler highlights the risks of marijuana use, including respiratory issues, mental health problems, and an increased risk of certain cancers cited by the National Institute on Drug Abuse, proponents of reclassification argue that marijuana has legitimate medical benefits. Forty-two states and Washington, D.C., have legalized medical marijuana, and 24 states permit recreational use. This widespread acceptance suggests that many view marijuana as less harmful than its Schedule I classification implies.
So, what’s the right move? Lawler firmly believes that reclassifying marijuana would be unwise, especially given the nation’s ongoing struggle with substance use disorders. ‘When you consider the challenges we face as a country with addiction, rescheduling marijuana doesn’t seem like a smart decision,’ he added. But is he right? Or is this a case of outdated stigma overshadowing potential benefits?
Here’s where you come in: Do you agree with Lawler’s stance, or do you think marijuana deserves a less severe classification? Is it a dangerous gateway drug, or a misunderstood medicine? Let’s keep the conversation going—share your thoughts in the comments below. The future of marijuana policy may just depend on it.
